ketorolac Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
anti-inflammatory agents, ibufenac derivatives 1529 74103-06-3

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • ketorolac
  • ketorolac tromethamine
  • ketorolac trometamol
  • trometamol ketorolac
  • (+/-)-Ketorolac
  • keromin
A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.
  • Molecular weight: 255.27
  • Formula: C15H13NO3
  • CLOGP: 1.62
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 59.30
  • ALOGS: -2.70
  • ROTB: 3

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg O
30 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 200 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 58 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 9.79 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.11 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.35 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 5.10 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 30, 1989 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 404.41 12.57 436 14186 243389 46428051
Spinal epidural haematoma 128.84 12.57 33 14589 755 46670685
Punctate keratitis 82.88 12.57 22 14600 581 46670859
Corneal epithelium defect 73.99 12.57 18 14604 331 46671109
Skin papilloma 71.65 12.57 32 14590 4144 46667296
Injury 65.94 12.57 75 14547 43952 46627488
Corneal oedema 61.11 12.57 22 14600 1624 46669816
Retinal pigment epitheliopathy 59.85 12.57 14 14608 216 46671224
Eye pain 56.78 12.57 56 14566 27884 46643556
Anterior chamber cell 55.98 12.57 16 14606 559 46670881
Treatment failure 52.58 12.57 100 14522 92987 46578453
Renal infarct 51.64 12.57 18 14604 1209 46670231
Extradural haematoma 49.03 12.57 18 14604 1405 46670035
Eye irritation 48.88 12.57 41 14581 16573 46654867
Purpura fulminans 46.27 12.57 9 14613 53 46671387
Tendon disorder 45.87 12.57 25 14597 4970 46666470
Quadriplegia 42.07 12.57 17 14605 1720 46669720
Ulcerative keratitis 40.71 12.57 18 14604 2275 46669165
Migraine 38.02 12.57 74 14548 69952 46601488
Uterine perforation 37.21 12.57 25 14597 7242 46664198
Emotional distress 35.66 12.57 46 14576 30661 46640779
Urinoma 35.60 12.57 7 14615 44 46671396
Corneal disorder 35.59 12.57 15 14607 1688 46669752
Aspirin-exacerbated respiratory disease 35.47 12.57 12 14610 736 46670704
Sleep disorder 33.78 12.57 56 14566 46739 46624701
Anaphylactic reaction 33.67 12.57 60 14562 53052 46618388
Endophthalmitis 31.75 12.57 17 14605 3261 46668179
Visual acuity reduced 30.29 12.57 36 14586 22077 46649363
Ocular hyperaemia 28.52 12.57 33 14589 19677 46651763
Vision blurred 28.25 12.57 71 14551 79637 46591803
Meniscus injury 26.86 12.57 19 14603 5977 46665463
Hypersensitivity 26.42 12.57 105 14517 150216 46521224
Concussion 26.41 12.57 20 14602 6983 46664457
Respiratory tract infection viral 24.76 12.57 12 14610 1869 46669571
Myelomalacia 24.37 12.57 5 14617 40 46671400
Musculoskeletal disorder 24.14 12.57 27 14595 15518 46655922
Sinusitis 23.89 12.57 92 14530 129676 46541764
Intraocular pressure increased 22.44 12.57 17 14605 5940 46665500
Renal ischaemia 22.16 12.57 8 14614 595 46670845
Spinal cord compression 22.10 12.57 14 14608 3670 46667770
Foreign body sensation in eyes 21.82 12.57 11 14611 1865 46669575
Asymptomatic bacteriuria 21.38 12.57 5 14617 77 46671363
Septic arthritis staphylococcal 21.00 12.57 7 14615 410 46671030
Photophobia 20.45 12.57 24 14598 14520 46656920
Dystonia 20.01 12.57 21 14601 11236 46660204
Kounis syndrome 19.95 12.57 9 14613 1193 46670247
Corneal thinning 19.58 12.57 5 14617 113 46671327
Paraplegia 19.30 12.57 11 14611 2383 46669057
Corneal abrasion 19.24 12.57 8 14614 870 46670570
Abdominal compartment syndrome 18.50 12.57 7 14615 594 46670846
Labelled drug-drug interaction medication error 18.10 12.57 18 14604 9043 46662397
Sphincter of Oddi dysfunction 17.96 12.57 6 14616 354 46671086
Diarrhoea 17.69 12.57 103 14519 559499 46111941
Post-traumatic stress disorder 16.24 12.57 12 14610 4036 46667404
Sensory loss 16.23 12.57 15 14607 6887 46664553
Corneal perforation 15.96 12.57 6 14616 500 46670940
Condition aggravated 15.89 12.57 131 14491 244921 46426519
Renal papillary necrosis 15.77 12.57 5 14617 250 46671190
Pain 15.52 12.57 222 14400 476726 46194714
Allodynia 15.42 12.57 6 14616 549 46670891
Embolia cutis medicamentosa 15.41 12.57 5 14617 269 46671171
Corneal scar 14.64 12.57 4 14618 118 46671322
Fascial infection 14.62 12.57 3 14619 24 46671416
Death 14.57 12.57 55 14567 335493 46335947
Respiratory depression 14.45 12.57 18 14604 11582 46659858
Urticaria 14.42 12.57 74 14548 117818 46553622
Corneal dystrophy 14.27 12.57 5 14617 341 46671099
Laryngeal dyspnoea 14.18 12.57 4 14618 133 46671307
Procedural pain 14.14 12.57 19 14603 13160 46658280
Corneal opacity 13.98 12.57 6 14616 706 46670734
Acute hepatic failure 13.97 12.57 20 14602 14701 46656739
Cataract 13.58 12.57 38 14584 45377 46626063
Post procedural haemorrhage 13.46 12.57 14 14608 7412 46664028
Internal injury 13.30 12.57 5 14617 417 46671023
Disease progression 13.24 12.57 6 14616 91294 46580146
Pupils unequal 13.10 12.57 7 14615 1337 46670103
Colitis ischaemic 13.06 12.57 16 14606 10116 46661324
Anxiety 12.72 12.57 99 14523 181858 46489582

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 91.59 15.88 92 6359 68427 29877600
Treatment failure 81.20 15.88 64 6387 34615 29911412
Ulcerative keratitis 56.07 15.88 18 6433 1371 29944656
Anaphylactic reaction 55.69 15.88 47 6404 27935 29918092
Aspirin-exacerbated respiratory disease 43.38 15.88 11 6440 356 29945671
Victim of child abuse 40.83 15.88 10 6441 280 29945747
Cataract 40.03 15.88 35 6416 21800 29924227
Burning feet syndrome 33.87 15.88 7 6444 88 29945939
Child abuse 27.99 15.88 7 6444 214 29945813
Corneal oedema 25.95 15.88 10 6441 1302 29944725
Corneal thinning 25.46 15.88 6 6445 142 29945885
Anterior chamber cell 24.26 15.88 7 6444 371 29945656
Periorbital swelling 23.79 15.88 6 6445 190 29945837
Superficial injury of eye 22.45 15.88 4 6447 21 29946006
Respiratory depression 22.21 15.88 19 6432 11484 29934543
Mixed liver injury 21.92 15.88 10 6441 1983 29944044
Eye pain 21.80 15.88 19 6432 11770 29934257
Urticaria 20.79 15.88 40 6411 54566 29891461
Punctate keratitis 20.76 15.88 6 6445 320 29945707
Anaesthetic complication neurological 20.60 15.88 6 6445 329 29945698
Corneal epithelium defect 20.60 15.88 6 6445 329 29945698
Nephrolithiasis 20.51 15.88 26 6425 24784 29921243
Eye disorder 19.65 15.88 15 6436 7719 29938308
Blood chromogranin A increased 19.56 15.88 5 6446 167 29945860
Angioedema 18.03 15.88 29 6422 34355 29911672
Carcinoid crisis 17.83 15.88 5 6446 239 29945788
Bone neoplasm 17.42 15.88 5 6446 260 29945767
Corneal abrasion 17.41 15.88 5 6446 261 29945766
Corneal opacity 17.37 15.88 6 6445 573 29945454
Corneal scar 16.61 15.88 4 6447 104 29945923
Sedation 16.54 15.88 19 6432 16354 29929673
Urine analysis abnormal 16.33 15.88 8 6443 1860 29944167

Pharmacologic Action:

SourceCodeDescription
ATC M01AB15 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Acetic acid derivatives and related substances
ATC S01BC05 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFLAMMATORY AGENTS
Antiinflammatory agents, non-steroids
ATC S01FB51 SENSORY ORGANS
OPHTHALMOLOGICALS
MYDRIATICS AND CYCLOPLEGICS
Sympathomimetics excl. antiglaucoma preparations
FDA CS M0001335 Anti-Inflammatory Agents, Non-Steroidal
FDA MoA N0000000160 Cyclooxygenase Inhibitors
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drugs
CHEBI has role CHEBI:50629 cyclooxygenase-2 inhibitor
CHEBI has role CHEBI:50630 cyclooxygenase-1 inhibitor
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
FDA EPC N0000175939 Cyclooxygenase Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Severe pain indication 76948002
Allergic conjunctivitis indication 473460002 DOID:11204
Acute postoperative pain indication 107401000119105
Postoperative Ocular Pain indication
Post-Op Ocular Inflammation indication
Post-Op Photophobia indication
Renal colic off-label use 7093002
Peptic ulcer contraindication 13200003 DOID:750
Disorder of cornea contraindication 15250008 DOID:10124
Acute gastric ulcer with perforation contraindication 19850005
Myocardial infarction contraindication 22298006 DOID:5844
Inflammatory bowel disease contraindication 24526004 DOID:0050589
Hypovolemia contraindication 28560003
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Tear film insufficiency contraindication 46152009
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Corneal erosion contraindication 50792001
Duodenal ulcer disease contraindication 51868009 DOID:1724
Acute nephropathy contraindication 58574008
Blood coagulation disorder contraindication 64779008 DOID:1247
Rheumatoid arthritis contraindication 69896004 DOID:7148
Diabetes mellitus contraindication 73211009 DOID:9351
Gastrointestinal hemorrhage contraindication 74474003
Hemophilia contraindication 90935002
Corneal degeneration contraindication 111521006 DOID:1237
Perioperative care contraindication 133897009
Asthma contraindication 195967001 DOID:2841
Impaired renal function disorder contraindication 197663003
Cerebrovascular accident contraindication 230690007
Coronary artery bypass graft contraindication 232717009
Disease of liver contraindication 235856003 DOID:409
Anemia contraindication 271737000 DOID:2355
Cerebral hemorrhage contraindication 274100004
Pregnancy, function contraindication 289908002
Cardiovascular event risk contraindication 395112001
Gastric ulcer contraindication 397825006 DOID:10808
Breastfeeding (mother) contraindication 413712001
Smokes tobacco daily contraindication 449868002
Preoperative Pain Management contraindication

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.47 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.3% BASE;EQ 1% BASE OMIDRIA OMEROS N205388 May 30, 2014 RX SOLUTION IRRIGATION June 8, 2021 PEDIATRIC EXCLUSIVITY

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 1 Enzyme INHIBITOR IC50 9.72 WOMBAT-PK CHEMBL
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 6.90 WOMBAT-PK CHEMBL
Aldose reductase Enzyme IC50 5.21 DRUG MATRIX
Prostaglandin-H2 D-isomerase Enzyme IC50 6.64 CHEMBL
Fatty acid-binding protein, liver Unclassified Ki 4.94 CHEMBL

External reference:

IDSource
4028637 VUID
N0000178380 NUI
D00813 KEGG_DRUG
74103-07-4 SECONDARY_CAS_RN
4019510 VANDF
4028637 VANDF
C0073631 UMLSCUI
CHEBI:6129 CHEBI
KTR PDB_CHEM_ID
CHEMBL469 ChEMBL_ID
CHEMBL1201124 ChEMBL_ID
D020910 MESH_DESCRIPTOR_UI
D020911 MESH_DESCRIPTOR_UI
DB00465 DRUGBANK_ID
6661 IUPHAR_LIGAND_ID
5558 INN_ID
YZI5105V0L UNII
3826 PUBCHEM_CID
28200 RXNORM
30341 MMSL
4947 MMSL
9780 MMSL
d00273 MMSL
003539 NDDF
004812 NDDF
108512006 SNOMEDCT_US
108513001 SNOMEDCT_US
372501008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Acular HUMAN PRESCRIPTION DRUG LABEL 1 0023-2181 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 25 sections
ACUVAIL HUMAN PRESCRIPTION DRUG LABEL 1 0023-3507 SOLUTION/ DROPS 4.50 mg OPHTHALMIC NDA 23 sections
ACULAR LS HUMAN PRESCRIPTION DRUG LABEL 1 0023-9277 SOLUTION/ DROPS 4 mg OPHTHALMIC NDA 22 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0093-0314 TABLET, FILM COATED 10 mg ORAL ANDA 27 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0069 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 27 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0072 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 27 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 0338-0076 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 27 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0378-1134 TABLET, FILM COATED 10 mg ORAL ANDA 19 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-2287 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-2288 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3793 INJECTION, SOLUTION 15 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3795 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0409-3796 INJECTION, SOLUTION 60 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0487-6232 INJECTION 30 mg INTRAMUSCULAR ANDA 15 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6041 INJECTION 15 mg INTRAMUSCULAR ANDA 17 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6042 INJECTION 30 mg INTRAMUSCULAR ANDA 17 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 0641-6043 INJECTION 30 mg INTRAMUSCULAR ANDA 17 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 10544-222 TABLET, FILM COATED 10 mg ORAL ANDA 29 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 12634-809 TABLET 10 mg ORAL ANDA 13 sections
ACULAR HUMAN PRESCRIPTION DRUG LABEL 1 16590-002 SOLUTION/ DROPS 5 mg OPHTHALMIC NDA 20 sections
KETOROLAC HUMAN PRESCRIPTION DRUG LABEL 1 16590-138 TABLET, FILM COATED 10 mg ORAL ANDA 15 sections
KETOROLAC TROMETHAMINE HUMAN PRESCRIPTION DRUG LABEL 1 16590-376 SOLUTION 5 mg OPHTHALMIC ANDA 18 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-207 SOLUTION/ DROPS 4.50 mg OPHTHALMIC ANDA 24 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-208 SOLUTION 4 mg OPHTHALMIC ANDA 20 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 17478-209 SOLUTION 5 mg OPHTHALMIC ANDA 25 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 21695-432 TABLET, FILM COATED 10 mg ORAL ANDA 29 sections
ACULAR HUMAN PRESCRIPTION DRUG LABEL 1 21695-463 SOLUTION 5 mg OPHTHALMIC NDA 10 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 21695-588 INJECTION, SOLUTION 30 mg INTRAMUSCULAR ANDA 23 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 21695-624 SOLUTION 4 mg OPHTHALMIC ANDA 22 sections
Ketorolac Tromethamine HUMAN PRESCRIPTION DRUG LABEL 1 21695-985 SOLUTION 4 mg OPHTHALMIC ANDA 22 sections